Author

Stuart H. Ellis

Observed names: S H Ellis, S. Ellis, S. H. Ellis, S.H. Ellis, Stuart Ellis

Observed institutions: King's College London, Royal Bournemouth Hospital, Hammersmith Hospital, Manchester Royal Infirmary, Northwick Park Hospital, King's College School, Alder Hey Children's Hospital

OpenAlex ID: A5109995057

Absorption of chlorhexidine from the intact skin of newborn infants.

1979 · J Cowen, S H Ellis, et al. · Archives of Disease in Childhood · 83

Cardioselectivity of atenolol in asthmatic patients

1981 · M. E. Ellis, J. N. Sahay, et al. · European Journal of Clinical Pharmacology · 67

Peripheral and autonomic nerve function in 259 diabetic patients with peripheral neuropathy treated with ponalrestat (an aldose reductase inhibitor) or placebo for 18 months

1992 · Göran Sundkvist, Frank M. Armstrong, et al. · Journal of Diabetes and its Complications · 59

A Study of Peripheral Diabetic Neuropathy. The Application of Age‐Related Reference Values

1991 · F. M. Armstrong, J. E. Bradbury, et al. · Diabetic Medicine · 59

Percutaneous absorption of chlorhexidine in neonatal cord care.

1981 · P J Aggett, L V Cooper, et al. · Archives of Disease in Childhood · 59

The effect on the skin flora of bathing with antiseptic solutions

1977 · Jean Davies, J. R. Babb, et al. · Journal of Antimicrobial Chemotherapy · 47

A 12‐Month Randomized Controlled Study of the Aldose Reductase Inhibitor Ponalrestat in Patients with Chronic Symptomatic Diabetic Neuropathy

1992 · A.J. Krentz, L. Honigsberger, et al. · Diabetic Medicine · 40

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials

2019 · Martin Schuler, Luis Paz-Ares, et al. · Lung Cancer · 31

Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib

2014 · Ingolf Griebsch, Michael Palmer, et al. · BMJ Open · 28

Analysis of duration of response in oncology trials

2007 · Stuart Ellis, Kevin J. Carroll, et al. · Contemporary Clinical Trials · 27

Six‐year results of a controlled trial of tamoxifen as single adjuvant agent in management of early breast cancer

1985 · A. J. Wilson, M. Baum, et al. · World Journal of Surgery · 25

Bioavailability of sustained release propranolol formulations

1981 · James McAinsh, Nigel S. Baber, et al. · Biopharmaceutics & Drug Disposition · 22

The analysis of a sequential clinical trial for the comparison of two lung cancer treatments

1983 · J. Whitehead, D. R. Jones, et al. · Statistics in Medicine · 20

Bioavailability of atenolol formulations

1980 · James McAinsh, Wilfred T. Simpson, et al. · Biopharmaceutics & Drug Disposition · 19

The effect of indomethacin on breathlessness in patients with diffuse parenchymal disease of the lung

1986 · Paul A. O'Neill, Trevor B. Stretton, et al. · British Journal of Diseases of the Chest · 17

Afatinib use in non-small cell lung cancer previously sensitive to epidermal growth factor receptor inhibitors: The United Kingdom Named Patient Programme

2014 · F. Khan, C. Ottensmeier, et al. · European Journal of Cancer · 12

P3.01-026 Analysis of Long-Term Response to First-Line Afatinib in the LUX-Lung 3, 6 and 7 Trials in Advanced EGFRm+ NSCLC

2017 · M. Schuler, J.C. Yang, et al. · Journal of Thoracic Oncology

Evaluation of Association of Progression-Free Survival (Pfs) with Health-Related Quality of Life (Hrqol) in Lung Cancer Patients (Pts)

2014 · Y. Wu, M. Palmer, et al. · Annals of Oncology

Works count: 19

Citation count: 615

H-index: 15

I10-index: 16